Business

Alnylam stock poised to climb, reports say

John Maraganore is chief executive of Cambridge-based Alnylam.

Bloomberg News/File 2007

John Maraganore is chief executive of Cambridge-based Alnylam.

Advertisement

Alnylam Pharmaceuticals Inc., which describes itself as a leading RNAi therapeutics company, had its price objective raised by Needham & Co. to $40 from $28 in a research report released this week, Analyst Ratings Network reported. The firm has a “buy” rating on the stock. Piper Jaffray recently raised its price target to $42.

Loading comments...